Menu
Search
|

Menu

Close
X

Shire PLC SHP.L (London Stock Exchange)

4,552.00 GBp
-32.00 (-0.70%)
As of Nov 21
chart
Previous Close 4,584.00
Open 4,594.50
Volume 359,904
3m Avg Volume 2,091,509
Today’s High 4,597.50
Today’s Low 4,546.50
52 Week High 4,780.00
52 Week Low 2,940.50
Shares Outstanding (mil) 915.64
Market Capitalization (mil) 41,952.80
Forward P/E 22.47
Dividend (Yield %) 4.26 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 16 analysts

KEY STATS

Revenue (mm, USD)
FY18
11,557
FY17
15,161
FY16
11,397
FY15
6,417
EPS (USD)
FY18
1.882
FY17
2.022
FY16
0.920
FY15
2.255
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
22.47
29.37
Price to Sales (TTM)
vs sector
3.47
20.58
Price to Book (MRQ)
vs sector
1.46
4.23
Price to Cash Flow (TTM)
vs sector
11.25
21.21
Total Debt to Equity (MRQ)
vs sector
41.15
13.84
LT Debt to Equity (MRQ)
vs sector
29.76
9.93
Return on Investment (TTM)
vs sector
4.18
13.58
Return on Equity (TTM)
vs sector
6.92
15.11

EXECUTIVE LEADERSHIP

Susan Kilsby
Non-Executive Chairman of the Board, Since 2014
Salary: --
Bonus: --
Flemming Ornskov
Chief Executive Officer, Executive Director, Since 2013
Salary: $1,688,000.00
Bonus: --
Thomas Dittrich
Chief Financial Officer, Executive Director, Since 2018
Salary: --
Bonus: --
Joanne Cordeiro
Chief Human Resource Officer, Since 2017
Salary: --
Bonus: --
Andreas Busch
Chief Scientific Officer, Head - Research and Development, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Miesian Plaza
50-58 Baggot Street Lower, Block
DUBLIN     D02 HW68

Phone: +3531.6096000

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience Ophthalmology, Hematology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

SPONSORED STORIES